Products
Antisoma focuses its activities on treatments for cancer, an area of significant unmet medical need.
Antisoma has a diverse portfolio of products in development. Our products target tumours by several different mechanisms and are intended for the treatment of a range of cancers.
ASA404 (DMXAA)
A Tumour-Vascular Disrupting Agent (Tumour-VDA) in phase III in first- and second-line NSCLC
More on ASA404AS1413 (amonafide L-malate)
A DNA intercalator in phase III in secondary AML
More on AS1413AS1411
A DNA aptamer in phase II in AML
More on AS1411AS1409 (huBC1-huIL12)
An antibody-cytokine fusion protein that has completed a phase I study in renal cell carcinoma and melanoma
More on AS1409